According to the Financial Times, Amgen will buy Celgene’s psoriasis drug Otezla for US$13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its US$74 billion deal for Celgene by the end of the year.
Amgen, which announced the deal on Monday, August 26, is paying a hefty price for the drug, analysts and investors said. Still, Otezla will deliver growth for the company right away and its shares rose around 2% in early trading.
Bristol-Myers stated in June that it would sell Otezla to allay concerns raised by the Federal Trade Commission because of a competing treatment that it is developing. Analysts said at the time that they were expecting Otezla to sell for around US$8 billion to US$10 billion.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.45
Please verify email or join us
to access premium content!
